Fibroblast growth factor-23: what we know, what we don't know, and what we need to know
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Traditional risk factors of cardiovascular morbidity and mortality such as hypertension, hypercholesterolemia and obesity are paradoxically associated with better outcomes in dialysis patients, and the few trials of interventions targeting modifiable traditional risk factors have yielded disappointing results in this patient population. Non-traditional risk factors such as inflammation, anemia and abnormalities in bone and mineral metabolism have been proposed as potential explanations for the excess mortality seen in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), but without clear understanding of what the most important pathophysiologic mechanisms of these risk factors are, which ones might be ideal treatment targets and which therapeutic interventions may be effective and safe in targeting them. Among the novel risk factors, fibroblast growth factor-23 (FGF23) has recently emerged as one of the most powerful predictors of adverse outcomes in patients with CKD and ESRD. FGF23 is a hormone produced by osteoblasts/osteocytes in bone that acts on the kidney to regulate phosphate and vitamin D metabolism through activation of FGF receptor/α-Klotho co-receptor complexes. It is possible that elevated FGF23 may exert its negative impact through distinct mechanisms of action independent from its role as a regulator of phosphorus homeostasis. Elevated circulating FGF23 concentrations have been associated with left ventricular hypertrophy (LVH), and it has been suggested that FGF23 exerts a direct effect on the myocardium. While it is possible that 'off target' effects of FGF23 present in very high concentrations could induce LVH, this possibility is controversial, since α-klotho is not expressed in the myocardium. Another possibility is that FGF23's effect on the heart is mediated indirectly, via 'on target' activation of other humoral pathways. We will review the physiology and pathophysiology of FGF23, the outcomes associated with elevated FGF23 levels, and describe putative mechanisms of action responsible for its negative effects and potential therapeutic strategies to treat these.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 1×
“Moreover, some of the traditional risk factors of CV morbidity and mortality such as African-American race, hypertension, hypercholesterolemia and obesity are paradoxically associated with better outcomes in CKD and ESRD patients [5–8], and the few trials of interventions targeting modifiable traditional CV risk facto…”
BackgroundFGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027 · cited 1×
“In a series of experiments from a single group of investigators, FGF23 was shown to induce LVH in vitro and in experimental animals by inducing molecular mechanisms typical of pathological LVH [70].”
BackgroundReceptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871 · cited 2×
“Since the myocardial cells do not express klotho, these experiments challenge the prevailing paradigm that FGF23’s effects on the FGFR are weak without the concomitant presence of klotho, even at high concentrations of FGF23 [32].”
BackgroundFibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Receptor Specificity of the Fibroblast Growth Factor Family
Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., & Ornitz, D. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601252200 · Cited by 1,164
Larsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Ferrari, S. L., Bonjour, J.-P., & Rizzoli, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1039 · Cited by 518 · cited 1×
“Studies that examined the effects of oral phosphate intake on FGF23 levels have detected either no effect [43–45], or described changes in FGF23 production in response to alterations in dietary phosphate intake after a lag time of up to 1 week [46–51].”
BackgroundEndocrine functions of bone in mineral metabolism regulation
Quarles, L. D. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36479 · Cited by 459 · cited 1×
“FGF23 is a regulator of phosphorus and vitamin D homeostasis, with its main bone and mineral-related physiologic actions being to increase renal phosphorus excretion and to decrease 1α-hydroxylation of 25OH vitamin D [19, 20].”
BackgroundSelf-citationDietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men
Antoniucci, D. M., Yamashita, T., & Portale, A. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0021 · Cited by 421
de Borst, M. H., Vervloet, M. G., ter Wee, P. M., & Navis, G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121251 · Cited by 282
Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men
Nishida, Y., Taketani, Y., Yamanaka-Okumura, H., Imamura, F., Taniguchi, A., Sato, T., Shuto, E., Nashiki, K., Arai, H., Yamamoto, H., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5002000 · Cited by 243
Effects of Dietary Phosphate and Calcium Intake on Fibroblast Growth Factor-23
Vervloet, M. G., van Ittersum, F. J., Büttler, R. M., Heijboer, A. C., Blankenstein, M. A., & ter Wee, P. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04730510 · Cited by 218 · cited 1×
“Studies that examined the effects of oral phosphate intake on FGF23 levels have detected either no effect [43–45], or described changes in FGF23 production in response to alterations in dietary phosphate intake after a lag time of up to 1 week [46–51].”
Background
Cited by
Vitamin D supplementation for prevention of mortality in adults
Bjelakovic, G., Gluud, L. L., Nikolova, D., Whitfield, K., Wetterslev, J., Simonetti, R. G., Bjelakovic, M., & Gluud, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007470.pub3 · Cited by 695
ter Maaten, J. M., Damman, K., Verhaar, M. C., Paulus, W. J., Duncker, D. J., Cheng, C., van Heerebeek, L., Hillege, H. L., Lam, C. S. P., Navis, G., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.497 · Cited by 320
Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease
Felsenfeld, A. J., Levine, B. S., & Rodriguez, M. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12411 · Cited by 189
Fifty Years of Human Space Travel: Implications for Bone and Calcium Research
Smith, S. M., Abrams, S. A., Davis-Street, J. E., Heer, M., O'Brien, K. O., Wastney, M. E., & Zwart, S. R. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071813-105440 · Cited by 111
Metadata
- Authors
- Kovesdy, C. P., & Quarles, L. D.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-25
- Volume
- 28
- Issue
- 9
- Pages
- 2228-2236
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2157248652
- Cited by
- 111
- References
- 13
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.